Aktienanalyse wird geladen …
VTRS · NASDAQ · Pharmaceuticals · USA
17,41 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 14,3 Mrd. | -3,51 Mrd. | -3,00 $ | 1,17 Mrd. | 10,2 Mio · 0,9 % | 35,2 Mio · 3 % | 35,1 % | -24,6 % | 1,65 $ | 0,15 $ | 0,48 $ |
| 2024 | 14,74 Mrd. | -634,2 Mio. | -0,53 $ | 1,2 Mrd. | 8,4 Mio · 0,7 % | — | 38,2 % | -4,3 % | 1,65 $ | 0,12 $ | 0,48 $ |
| 2023 | 15,43 Mrd. | 54,7 Mio. | 0,05 $ | 1,21 Mrd. | 10,4 Mio · 0,9 % | 20,9 Mio · 1,7 % | 41,7 % | 0,4 % | 2,09 $ | 0,15 $ | 0,48 $ |
| 2022 | 16,26 Mrd. | 2,08 Mrd. | 1,71 $ | 1,22 Mrd. | 6,7 Mio · 0,5 % | — | 40 % | 12,8 % | 2,13 $ | 0,10 $ | 0,48 $ |
| 2021 | 17,89 Mrd. | -1,27 Mrd. | -1,05 $ | 1,21 Mrd. | 6,4 Mio · 0,5 % | — | 31,2 % | -7,1 % | 2,12 $ | 0,09 $ | 0,33 $ |
| 2020 | 11,95 Mrd. | -669,9 Mio. | -1,11 $ | 601,2 Mio. | 4,5 Mio · 0,8 % | — | 31,8 % | -5,6 % | 1,64 $ | 0,13 $ | — |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Bruttomarge | Nettomarge | FCF / Aktie |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 3,76 Mrd. | -118,8 Mio. | -0,10 $ | 1,16 Mrd. | 38,8 % | -3,2 % | 0,28 $ |
| Q1 2026 | 3,52 Mrd. | 176,4 Mio. | 0,15 $ | 1,18 Mrd. | 32,9 % | 5 % | 0,30 $ |
| Q4 2025 | 3,7 Mrd. | — | — | 1,15 Mrd. | 31 % | — | 0,53 $ |
| Q3 2025 | 3,76 Mrd. | -128,2 Mio. | -0,11 $ | 1,16 Mrd. | 36,5 % | -3,4 % | 0,57 $ |
| Q2 2025 | 3,58 Mrd. | -4,6 Mio. | 0,00 $ | 1,17 Mrd. | 37,2 % | -0,1 % | 0,14 $ |
| Q1 2025 | 3,25 Mrd. | -3,04 Mrd. | -2,55 $ | 1,19 Mrd. | 35,7 % | -93,5 % | 0,41 $ |
| Q4 2024 | 3,53 Mrd. | — | — | — | 34,4 % | — | 0,29 $ |
| Q3 2024 | 3,75 Mrd. | 94,8 Mio. | 0,08 $ | 1,2 Mrd. | 38,9 % | 2,5 % | 0,62 $ |
Is Viatris Stock Outperforming the S&P 500?
Viatris Facing Multiple Paths to Earnings Growth, Oppenheimer Says
Oppenheimer Initiates Viatris at Outperform With $25 Price Target
Viatris (VTRS) Wins Japan WAKIX Approval. Can it Build a Meaningful Specialty Business?
Viatris Says Wakix Wins Japan Approval for Narcolepsy, Obstructive Sleep Apnea
Viatris Inc. is a global healthcare company focused on expanding access to a broad range of medicines across multiple therapeutic areas. Its portfolio includes established prescription brands, generic and complex generic medicines, biosimilars, and over-the-counter consumer products that support treatment and disease management worldwide. Viatris serves patients and healthcare systems in developed and emerging markets through operations organized across Developed Markets, Greater China, JANZ, and Emerging Markets. The company also emphasizes reliable manufacturing, distribution, and supply continuity for essential therapies, helping connect more people to trusted medicines regardless of geography or circumstance. Headquartered in Canonsburg, Pennsylvania, Viatris operates as a diversified pharmaceutical business with a broad international footprint and a focus on scalable healthcare access.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest VTRS und jede andere Aktie unbegrenzt.